Targeting oncogenic PIM1 kinase activation in T-cell acute lymphoblastic leukemia and lymphoma Ghent University
T-cell acute lymphoblastic leukemia and lymphoma (T-ALL/T-LBL) are aggressive hematologic malignancies that require treatment with intensified chemotherapy. PIM1 is a constitutively active kinase that is overexpressed in a large number of cancer subtypes. Several PIM inhibitors are currently tested in clinical trials for the treatment of different malignancies. The identification of a PIM1 translocation in a case of human T-LBL and the notion ...